Last reviewed · How we verify
Herpes simplex dendritic keratitis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Cytovene | GANCICLOVIR | Roche Palo | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor | Metabotropic glutamate receptor 1 | 1989-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 1 drug in Herpes simplex dendritic keratitis
- Roche Palo · 1 drug in Herpes simplex dendritic keratitis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Herpes simplex dendritic keratitis:
- Herpes simplex dendritic keratitis treatment updates — RSS
- Herpes simplex dendritic keratitis treatment updates — Atom
- Herpes simplex dendritic keratitis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Herpes simplex dendritic keratitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/herpes-simplex-dendritic-keratitis. Accessed 2026-06-10.
Related
- Herpes simplex dendritic keratitis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing